These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

528 related articles for article (PubMed ID: 32051167)

  • 21. Single tube liquid biopsy for advanced non-small cell lung cancer.
    de Wit S; Rossi E; Weber S; Tamminga M; Manicone M; Swennenhuis JF; Groothuis-Oudshoorn CGM; Vidotto R; Facchinetti A; Zeune LL; Schuuring E; Zamarchi R; Hiltermann TJN; Speicher MR; Heitzer E; Terstappen LWMM; Groen HJM
    Int J Cancer; 2019 Jun; 144(12):3127-3137. PubMed ID: 30536653
    [TBL] [Abstract][Full Text] [Related]  

  • 22. DNA methylation biomarkers discovered
    Vrba L; Oshiro MM; Kim SS; Garland LL; Placencia C; Mahadevan D; Nelson MA; Futscher BW
    Epigenetics; 2020 Apr; 15(4):419-430. PubMed ID: 31775567
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relationship between circulating lung-specific X protein messenger ribonucleic acid expression and micrometastasis and prognosis in patients with early-stage nonsmall cell lung cancer.
    Cui Y; Wang W; Yao S; Qiu Z; Cong L
    J Cancer Res Ther; 2020; 16(7):1641-1647. PubMed ID: 33565511
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of Liquid Biopsy in the Care of Patients with Non-Small Cell Lung Cancer.
    Romero A; Serna-Blasco R; Calvo V; Provencio M
    Curr Treat Options Oncol; 2021 Aug; 22(10):86. PubMed ID: 34424428
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Liquid biopsy in breast cancer: A comprehensive review.
    Alimirzaie S; Bagherzadeh M; Akbari MR
    Clin Genet; 2019 Jun; 95(6):643-660. PubMed ID: 30671931
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Liquid Biopsy and Lung Cancer.
    Pisapia P; Malapelle U; Troncone G
    Acta Cytol; 2019; 63(6):489-496. PubMed ID: 30566947
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Integrating circulating-free DNA (cfDNA) analysis into clinical practice: opportunities and challenges.
    García-Pardo M; Makarem M; Li JJN; Kelly D; Leighl NB
    Br J Cancer; 2022 Sep; 127(4):592-602. PubMed ID: 35347327
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of circulating-tumor DNA analysis in non-small cell lung cancer.
    Jiang T; Ren S; Zhou C
    Lung Cancer; 2015 Nov; 90(2):128-34. PubMed ID: 26415994
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular profiling and utility of cell-free DNA in nonsmall carcinoma of the lung: Study in a tertiary care hospital.
    Ghosh M; Mukhopadhyay M; Das C; Chatterjee S; Naskar BG
    J Cancer Res Ther; 2021; 17(6):1389-1396. PubMed ID: 34916369
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients?
    Hofman P; Heeke S; Alix-Panabières C; Pantel K
    Ann Oncol; 2019 Sep; 30(9):1448-1459. PubMed ID: 31228184
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Application of liquid biopsy in bone and soft tissue sarcomas: Present and future.
    Li X; Seebacher NA; Hornicek FJ; Xiao T; Duan Z
    Cancer Lett; 2018 Dec; 439():66-77. PubMed ID: 30223067
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Making the Rounds: Exploring the Role of Circulating Tumor DNA (ctDNA) in Non-Small Cell Lung Cancer.
    Shields MD; Chen K; Dutcher G; Patel I; Pellini B
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012272
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Research progress of circulating tumor DNA methylation in non-small cell lung cancer].
    Yang Lan L; Chen Bojiang BJ; Li Lei L
    Zhonghua Jie He He Hu Xi Za Zhi; 2018 Dec; 41(12):967-970. PubMed ID: 30522195
    [No Abstract]   [Full Text] [Related]  

  • 34. Liquid biopsy in non-small cell lung cancer: a key role in the future of personalized medicine?
    Pi C; Zhang MF; Peng XX; Zhang YC; Xu CR; Zhou Q
    Expert Rev Mol Diagn; 2017 Dec; 17(12):1089-1096. PubMed ID: 29057681
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Liquid biopsy: current technology and clinical applications.
    Nikanjam M; Kato S; Kurzrock R
    J Hematol Oncol; 2022 Sep; 15(1):131. PubMed ID: 36096847
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Liquid biopsy and minimal residual disease - latest advances and implications for cure.
    Pantel K; Alix-Panabières C
    Nat Rev Clin Oncol; 2019 Jul; 16(7):409-424. PubMed ID: 30796368
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cell-free tumour DNA as a diagnostic and prognostic biomarker in non-small cell lung carcinoma.
    Łochowska BA; Nowak D; Białasiewicz P
    Adv Respir Med; 2019; 87(2):118-122. PubMed ID: 31038724
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer.
    Guibert N; Jones G; Beeler JF; Plagnol V; Morris C; Mourlanette J; Delaunay M; Keller L; Rouquette I; Favre G; Pradines A; Mazieres J
    Lung Cancer; 2019 Nov; 137():1-6. PubMed ID: 31518912
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Liquid biopsy in newly diagnosed patients with locoregional (I-IIIA) non-small cell lung cancer.
    Chen K; Kang G; Zhao H; Zhang K; Zhang J; Yang F; Wang J
    Expert Rev Mol Diagn; 2019 May; 19(5):419-427. PubMed ID: 30905203
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Circulating tumour DNA: A new biomarker to monitor resistance in NSCLC patients treated with EGFR-TKIs.
    Diao Z; Han Y; Zhang R; Li J
    Biochim Biophys Acta Rev Cancer; 2020 Apr; 1873(2):188363. PubMed ID: 32275933
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.